Traws Pharma (TRAW) – Analysts’ Recent Ratings Changes

Traws Pharma (NASDAQ: TRAW) has recently received a number of price target changes and ratings updates:

• 12/6/2025 – Traws Pharma was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 12/4/2025 – Traws Pharma was upgraded by analysts at Zacks Research to a “hold” rating.
• 12/3/2025 – Traws Pharma is now covered by analysts at HC Wainwright. They set a “buy” rating and a $8.00 price target on the stock.
• 12/3/2025 – Traws Pharma is now covered by analysts at HC Wainwright. They set a “buy” rating and a $8.00 price target on the stock.
• 12/1/2025 – Traws Pharma had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Traws Pharma had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/1/2025 – Traws Pharma was upgraded by analysts at Wall Street Zen to a “hold” rating.
• 10/30/2025 – Traws Pharma had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.